SAN CARLOS, Calif., September 28, 2016 /PRNewswire/ — Natera, Inc. (NASDAQ: NTRA), a pacesetter in non invasive genetic screening and also the evaluation of moving cell free genetics, today declared that it’ll launch outcomes because of its second-quarter ended June 30, 2016 following the marketplace close on July 4, 2016. Natera can host a conference phone and webcast at 1:30 p.m. Rehabilitation (4:30 p.m. ET) to go over its economic outcomes, company actions and economic perspective.
Natera is just a genetic screening organization that commercializes and grows non-invasive for examining DNA methods. The company’s objective would be to change administration and the analysis of genetic illness. In search of that objective, Natera works a LIMIT-certified lab licensed underneath the Medical Laboratory Improvement Changes (CLIA) in San Carlos, California, also it presently provides a sponsor of amazing genetic screening solutions mainly to OB/GYN doctors and fertility facilities, in addition to to genetic labs through its cloud-based Constellation&industry; application program. Assessments range from the Range® pre-implantation genetic examination for embryo choice during IVF; the Anora® miscarriage check to comprehend the innate reasons for a pregnancy reduction; the Skyline&industry; provider display to identify inherited variations; and also the Panorama® non invasive prenatal check (NIPT) to display for typical genetic defects in a baby as soon as eight months of pregnancy. Natera can also be implementing its systems that are distinctive to build up non-invasive analytical resources and testing for enhanced treatment of cancer and earlier recognition. These assessments authorized or haven’t been removed from the U.S. Food.
Mike Brophy, 650 249 9091 ext. 1471
Laura Zobkiw, 650 249 9091 ext. 1649
SUPPLY Natera, Inc.